Boehringer Ingelheim and IBM Collaborate to Advance Generative AI and Foundation Models for Therapeutic Antibody Development

[ad_1] Ingelheim, Germany and Armonk N.Y., November 28, 2023 – Today, Boehringer Ingelheim and IBM (NYSE:IBM) announced an agreement that will enable Boehringer to use IBM’s foundation model technologies to discover…

Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Met Primary Endpoint of Progression-Free Survival in Phase III Trial for First-Line Treatment of Recurrent/Metastatic Cervical Cancer in All-Comer Patients

[ad_1] HONG KONG, Nov. 27, 2023 /PRNewswire/ — Akeso (9926. HK) has announced that the AK104-303 Phase III trial, which investigated cadonilimab (Akeso’s PD-1/CTLA-4 bispecific antibody) combined with platinum-based chemotherapy +/-…

‘Very angry’: Parents struggle to get newborns preventive RSV antibody

[ad_1] Many parents are waiting to get a new preventive antibody for their babies to prevent them from getting sick with bronchiolitis. Experts and officials say the product is a…

FDA advisors recommend AstraZeneca, Sanofi antibody to protect babies from RSV

[ad_1] A panel of independent advisors to the Food and Drug Administration unanimously recommended Thursday that the antibody nirsevimab be approved for use to protect infants from respiratory syncytial virus,…

Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting

[ad_1] ROCKVILLE, Md. and SUZHOU, China, June 3, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the…

VEGFA Antibody Market Business Plan, Manufacturing Process, Raw Materials, Plant Cost, Industry Trends, Machinery Requirements forecast 2030

[ad_1]

Upcoming Opportunities in Human Combinatorial Antibody Libraries (HuCAL) Market Business Strategies, Current Insights, Regional Developments, Demand and Forecast to 2030

[ad_1] Contact Us: Stratagem Market Insights UK: +44-203-289-4040 Email: [email protected] 

FDA pulls authorization for AstraZeneca’s Covid antibody drug Evusheld

[ad_1] The Food and Drug Administration has withdrawn emergency use authorization for AstraZeneca’s Covid-19 antibody cocktail Evusheld as the treatment is not expected to neutralize the currently dominant XBB.1.5 subvariant of…

FDA withdraws Covid antibody treatment Evusheld because it’s not effective against 93% of subvariants

[ad_1] Evusheld (tixagevimab and cilgavimab) injection, a new COVID-19 treatment that people can take before becoming symptomatic. (Chris Sweda/Chicago Tribune/Tribune News Service via Getty Images) Chris Sweda | Tribune News…